There are 2789 resources available
1379P - Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
Presenter: Daniel Catenacci
Session: ePoster Display
1380P - Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Presenter: Geoffrey Ku
Session: ePoster Display
1381P - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
Presenter: Markus Moehler
Session: ePoster Display
1382P - Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer
Presenter: Jeeyun Lee
Session: ePoster Display
1383P - Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer
Presenter: Yasutoshi Kuboki
Session: ePoster Display
1410P - Gastric cancer: Data from the AGAMENON-SEOM study
Presenter: Ismael Macias Declara
Session: ePoster Display
1321P - Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
Presenter: Hiroshi Nokihara
Session: ePoster Display
1322P - Development and external validation of a novel four-gene-pair signature for predicting clinical response to anti-PD-1 immunotherapy of non-small cell lung cancer
Presenter: Chengming Liu
Session: ePoster Display
1323P - Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice
Presenter: Drazena Srdic
Session: ePoster Display
1324P - Clinical and laboratory features: How they influence immunotherapy response in non-small cell lung cancer
Presenter: Ricardo Gomes
Session: ePoster Display